The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.
Price target range & 52-week position
Bear₹2.38Fair value₹5.79Bull₹11.26
FairClose
52-week traded range
52W low ₹3.4452W high ₹5.85
The 52-week range is measured from the stored price history, not estimated.
Valuation summary
Trading below the consensus fair value
Ajooni Biotech Limited closed at ₹3.50, 39.6% below the consensus fair value of ₹5.79 drawn from 8 valuation models.
Financial DNA score 53/100 — Good. P/E of 15.1x against the 20x sector multiple the P/E model uses.
Quantitative summary only — not investment advice.
All valuation models
DCF Valuation
₹4.96
+41.8%
Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10
g=9%, r=10%, tg=3%, n=10yr
Graham Formula
₹11.26
+221.7%
EPS × (8.5 + 2g) × 6.5 ÷ FD_Rate
g=20%, FD=7%
P/E Fair Value
₹5.05
+44.3%
EPS × 20.2x (sector P/E)
EPS=0.25, Sector P/E=20.2x
Peter Lynch (PEG)
₹6.25
+78.6%
EPS × Growth% (PEG = 1 is fair)
EPS=0.25, g=25%
EV/EBITDA
₹7.35
+110.0%
(EBITDA × 18x − Net Debt) ÷ Shares
EBITDA=80M
Book Value (P/B)
₹2.38
-32.1%
BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]
BVPS=4.93, ROE=4.8%, g=6%, r=10%
Reverse DCF
₹3.50
+0.0%
Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV
Implied: 2.3% | Historical: 25%
Margin of Safety
₹5.32
+51.9%
Avg(DCF, Graham, P/E) × 75% (25% safety buffer)
Avg fair value=7.09, MoS=25%
Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.
Educational data only. Not a recommendation to buy, sell or hold any security.